BMD Biomarker Outcomes With Elinzanetant vs Placebo: Clinical Relevance and Implications

EP: 1.Impact of Menopause on Bone Health and Fracture Risk

EP: 2.Therapies for Vasomotor Symptoms and Their Effects on Bone Mineral Density

EP: 3.Neurokinin Therapies for VMS: MOAs and Potential Bone Health Implications

EP: 4.OASIS-3 Trial and Bone Mineral Density Subanalysis: Design, Methods, and End Points

Now Viewing

EP: 5.BMD Biomarker Outcomes With Elinzanetant vs Placebo: Clinical Relevance and Implications

EP: 6.OASIS-3 Subanalysis: Weight and Muscle Mass Outcomes With Elinzanetant

Video content above is prompted by the following:

The OASIS-3 bone mineral density (BMD) subanalysis evaluated 3 key measures: bone mineral density via DEXA scanning at the lumbar spine, femoral neck, and total hip; bone turnover markers including P1NP, osteocalcin, and bone-specific alkaline phosphatase; and bioelectrical impedance analysis for total body bone density estimation. Results showed elinzanetant demonstrated less decrease in bone mineral density compared to placebo across all measured sites.

Bone turnover marker analysis revealed that elinzanetant treatment was associated with smaller increases in remodeling markers, suggesting potentially reduced bone turnover activity. Additionally, bioelectrical impedance analysis showed increased total body bone density with elinzanetant compared to placebo, providing convergent evidence for beneficial skeletal effects.

These findings suggest that elinzanetant may offer dual benefits for postmenopausal women by addressing vasomotor symptoms while potentially protecting against bone loss. This combination of effects represents a significant advantage for treating patients at high risk for bone loss during the menopausal transition, potentially improving long-term skeletal health outcomes while managing troublesome symptoms.